Imaging cerebral waste clearance responses during exosome treatment of diabetes

This research project aims to evaluate how exosome-based therapies influence the brain's mechanisms for clearing metabolic and proteostatic waste in the context of diabetes. Diabetes is associated with systemic metabolic dysregulation that can adversely affect the central nervous system, including alterations in cerebrovascular function, accumulation of metabolic byproducts, and impaired clearance of proteins and cellular debris. The project focuses on visualizing and quantifying cerebral waste clearance processes often described collectively as the brain's glymphatic and perivascular clearance systems before, during, and after administration of therapeutic exosomes in experimental models relevant to diabetes. Using advanced imaging modalities, the study will map dynamic fluid and solute movement through perivascular pathways and assess how exosome treatment modulates these processes. Key objectives include establishing imaging protocols sensitive to changes in interstitial solute transport, determining whether exosome therapy restores or enhances clearance pathways compromised by diabetic pathology, and identifying imaging biomarkers that correlate with functional improvements.

The research will develop and apply longitudinal imaging strategies to capture both acute and longer-term responses in cerebral clearance, enabling correlation of imaging findings with biochemical and histological measures of waste burden, inflammation, and vascular integrity. By integrating multimodal imaging readouts with molecular analyses, the project seeks to define mechanistic links between exosome-driven signaling and restoration of perivascular fluid dynamics. Particular attention will be given to the spatial and temporal patterns of clearance changes across vulnerable brain regions known to accumulate metabolic waste in diabetes. The study will also evaluate dose and timing parameters for exosome administration to determine optimal regimens for promoting clearance without adverse effects. Successful completion of this work could yield several important outcomes: validated imaging approaches to monitor cerebral waste clearance in preclinical diabetes models; evidence for exosome-mediated modulation of clearance pathways; candidate imaging biomarkers for translation to clinical studies; and mechanistic insights into how cellular vesicle therapies interact with neurovascular and interstitial compartments.

These deliverables would support the design of future clinical investigations of exosome therapies in people with diabetes at risk for cognitive decline and neurodegenerative complications. The project adheres to rigorous methodological standards for imaging, quantification, and replication to ensure robust, interpretable results. Throughout, the team will emphasize reproducibility and potential translatability, positioning the work as a foundation for leveraging imaging biomarkers in therapeutic development. In sum, this study addresses a critical gap by directly imaging how exosome treatment impacts the brain's waste clearance machinery in diabetes, with the goal of informing therapeutic strategies that mitigate neurologic sequelae associated with metabolic disease.